DVHG.F Stock Overview
Devonian Health Group Inc. engages in the development of botanical drugs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Devonian Health Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.17 |
| 52 Week High | CA$0.21 |
| 52 Week Low | CA$0.16 |
| Beta | 1.53 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -58.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| DVHG.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.01% | 2.0% |
| 1Y | n/a | 9.5% | 22.3% |
Return vs Industry: Insufficient data to determine how DVHG.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DVHG.F performed against the US Market.
Price Volatility
| DVHG.F volatility | |
|---|---|
| DVHG.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DVHG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DVHG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 7 | Luc Gregoire | groupedevonian.com |
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Devonian Health Group Inc. Fundamentals Summary
| DVHG.F fundamental statistics | |
|---|---|
| Market cap | US$23.91m |
| Earnings (TTM) | -US$3.14m |
| Revenue (TTM) | US$3.69m |
6.5x
P/S Ratio-7.6x
P/E RatioIs DVHG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVHG.F income statement (TTM) | |
|---|---|
| Revenue | CA$5.03m |
| Cost of Revenue | CA$3.12m |
| Gross Profit | CA$1.91m |
| Other Expenses | CA$6.19m |
| Earnings | -CA$4.28m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 37.90% |
| Net Profit Margin | -85.08% |
| Debt/Equity Ratio | 0% |
How did DVHG.F perform over the long term?
See historical performance and comparison